---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References"
description: "Reference list for the formulary evidence report on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks. 209 cited documents."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References

<a id="references"></a>

## 5 References

1. [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)
2. [Adatia et al. (2026)](https://ir.pharvaris.com/static-files/9ecee56b-8c9c-475e-8f67-04661081af79)
3. [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)
4. [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)
5. [Anderson et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13290826/)
6. [Anderson et al. (2026b)](https://link.springer.com/article/10.1007/s12325-026-03790-2)
7. [Anderson et al. (2026c)](https://ir.pharvaris.com/static-files/9d17729a-c3ad-4b4b-a355-40e360776318)
8. [Arora et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37558360/)
9. [Aygören-Pürsün et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4105891/)
10. [Aygören-Pürsün et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5019462/)
11. [Aygören-Pürsün et al. (2026a)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2826%2900004-9/fulltext)
12. [Aygören-Pürsün et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273462/)
13. [Banta et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21781409/)
14. [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/)
15. [Bernstein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12626162/)
16. [Betschel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271048/)
17. [Betschel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12093744/)
18. [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)
19. [Blasco et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3584739/)
20. [Bork et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12767961/)
21. [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/)
22. [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/)
23. [Bui et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42635583/)
24. [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)
25. [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/)
26. [Buttgereit et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12306030/)
27. [Caballero et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24268449/)
28. [California HCAI five-year WAC increase history (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/d754c567-c3c3-4ecf-a236-8144578549dd/download/5-year-wac-increase-history-jan-oct-2026.csv)
29. [California HCAI prescription drugs introduced to market (2019)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/6393cda0-6101-424e-b738-07aee9e6f94f/download/q1-q4-2019-prescription-drugs-introduced-to-market.xlsx)
30. [California HCAI prescription drugs introduced to market (2020)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/9a37709e-4151-4300-a031-91ea7813da60/download/q1-q4-2020-prescription-drugs-introduced-to-market.xlsx)
31. [California HCAI prescription drugs introduced to market (2021)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/5a80b890-24bb-4d66-a0bb-d6c46a150065/download/q1-q4-2021-prescription-drugs-introduced-to-market.xlsx)
32. [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx)
33. [California HCAI prescription drugs introduced to market (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv)
34. [California HCAI WAC increase data (2024)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/882bb30d-44ed-48c9-b722-beb5aedc2c1b/download/q1-q4-2024-prescription-drug-wac-increases.xlsx)
35. [California HCAI WAC increase data (2025)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/46b78eef-5952-4fff-84c7-1fa758990ce8/download/q1-q4-2025-prescription-drug-wac-increases.xlsx)
36. [California HCAI WAC increase data (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-oct-2026.csv)
37. [Cancian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12590309/)
38. [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)
39. [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/)
40. [Christiansen et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25715243/)
41. [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)
42. [Christiansen et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39694088/)
43. [Christiansen et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12123198/)
44. [Christiansen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488251/)
45. [Cicardi et al. (2010a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4662377/)
46. [Cicardi et al. (2010b)](https://pubmed.ncbi.nlm.nih.gov/20818887/)
47. [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf)
48. [Cigna Ekterly prior authorization policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0756_coveragepositioncriteria_hereditary_angioedema_ekterly.pdf)
49. [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)
50. [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)
51. [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)
52. [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)
53. [ClinicalTrials.gov NCT07759141](https://clinicaltrials.gov/study/NCT07759141)
54. [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)
55. [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)
56. [CMS Medicare Part D Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/98218f98-166c-4723-8438-c344a4ef96a6/DSD_PTD_RY26_P04_V10_DY24_BGM.csv)
57. [Cohn et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10476273/)
58. [Cohn et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39724968/)
59. [Cohn et al. (2026)](https://ir.pharvaris.com/static-files/8ea05186-a535-4842-bb06-c31a4994fbea)
60. [CountyCare acute HAE products guideline (2026)](https://countycare.com/wp-content/uploads/ECG_5000.CC-for-Acute-Hereditary-Angioedema-Products-ver-Jan-26.pdf)
61. [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)
62. [Craig et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19767078/)
63. [Craig et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33980328/)
64. [Craig et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327167/)
65. [Craig et al. (2026b)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)
66. [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)
67. [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)
68. [CTIS.eu 2023-506305-18-01](https://ctis.eu/trial/2023-506305-18-01)
69. [CTIS.eu 2024-514713-35-00](https://ctis.eu/trial/2024-514713-35-00)
70. [Cycle SAJAZIR prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1756aca0-21a1-4898-8d6c-9666738db45c)
71. [Danielsson et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-2-2/current-use-of-hereditary-angioedema-hae-treatments-in-sweden-an-analysis-of-the-national-prescribed-drug-register)
72. [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://department.va.gov/procurement-acquisition-and-logistics/wp-content/uploads/sites/56/2026/11/TPharmPrices-11-01-2026.xlsx)
73. [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)
74. [EMA orphan designation EU/3/25/3040 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3040)
75. [EMA paediatric investigation plan decision P/0411/2023 (2023)](https://www.ema.europa.eu/en/documents/pip-decision/p-0411-2023-ema-decision-25-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-deucrictibant-emea-003090-pip02-22_en.pdf)
76. [EMA paediatric investigation plan modification EMA/PE/0000227462 (2025)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000227462)
77. [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES)
78. [Farkas et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40886933/)
79. [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)
80. [FDA (2022)](https://www.fda.gov/media/75907/download)
81. [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf)
82. [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)
83. [FDA Drug Trials Snapshot EKTERLY](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)
84. [FDA ORLADEYO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214094s006lbl.pdf)
85. [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=809521)
86. [FDA TAKHZYRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761090s020lbl.pdf)
87. [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/)
88. [Fijen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36990433/)
89. [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/)
90. [G-BA sebetralstat resolution justification (2026)](https://www.g-ba.de/downloads/40-1465-12519/2026-04-02_AM-RL-XII_Sebetralstat_D-1248_TrG_EN.pdf)
91. [Gallop et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2740956)
92. [Groen et al. (2021)](https://ir.pharvaris.com/static-files/f7f8b87d-c488-4611-b3a6-a2275aa94143)
93. [Grover et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12541594/)
94. [Grumach et al. (2026)](https://ir.pharvaris.com/static-files/4dee9ac5-c7f0-489f-8d8a-197fc1d5da1a)
95. [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)
96. [HAS EKTERLY transparency committee opinion (2026)](https://www.has-sante.fr/upload/docs/evamed/CT-21620_EKTERLY_PIC_INS_AvisDef_CT21620.pdf)
97. [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)
98. [Heuring et al. (2026)](https://www.primetherapeutics.com/documents/d/primetherapeutics/EVT_EXT_670100-H_AMCPPstr_RealWorldPatternsOfOnDemandUtilization_R4-2_Web)
99. [Hummel et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03836-5)
100. [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)
101. [Intellia Therapeutics AAAAI poster (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_KKS-Modeling-Poster_with-Supplement.pdf)
102. [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)
103. [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)
104. [KalVista Pharmaceuticals Colorado WAC disclosure (2026)](https://www.kalvista.com/wp-content/uploads/2026/05/Colorado-WAC-Disclosure-Ekterly-updated-20260504.pdf)
105. [Kawalec et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3834719/)
106. [Khalid and Hitch (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12276015/)
107. [Kim et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25280464/)
108. [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)
109. [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)
110. [Leibovich-Nassi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10092815/)
111. [Lesage et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7316994/)
112. [Lesage et al. (2021)](https://ir.pharvaris.com/static-files/76beb63f-4ccf-482a-933d-d2b47ec4e09d)
113. [Lesage et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35086057/)
114. [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)
115. [Lesage et al. (2026b)](https://ir.pharvaris.com/static-files/67d704cc-422d-47b0-b130-9a6556fce46a)
116. [Leung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630838/)
117. [Levy et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20568386/)
118. [Li et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36584968/)
119. [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909897/)
120. [Lo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8864034/)
121. [Lochbaum et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43025858/)
122. [Longhurst et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11638394/)
123. [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)
124. [Lumry et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20929608/)
125. [Lumry et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22123383/)
126. [Lumry et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39586588/)
127. [Maurer et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3563637/)
128. [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)
129. [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)
130. [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)
131. [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)
132. [McMillan et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22462765/)
133. [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)
134. [Meisgen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13461400/)
135. [Mendivil et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7893968/)
136. [Mendivil et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12953491/)
137. [Minafra et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34687444/)
138. [Minafra et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35526778/)
139. [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx)
140. [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance)
141. [NICE sebetralstat project page (2026)](https://www.nice.org.uk/guidance/indevelopment/gid-ta11334)
142. [O'Connor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12320545/)
143. [Olson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41429313/)
144. [Onderzoekmetmensen.nl NL-OMON49496](https://onderzoekmetmensen.nl/en/node/49496)
145. [Onderzoekmetmensen.nl NL-OMON49587](https://www.onderzoekmetmensen.nl/en/node/49587)
146. [Petersen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38609017/)
147. [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf)
148. [Pharvaris 2025 strategic priorities press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025004542/phvs-ex99_1.htm)
149. [Pharvaris 2026 strategic priorities press release (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526009705/phvs-ex99_1.htm)
150. [Pharvaris AAAAI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/deucrictibant-data-supporting-potentially-differentiated-profile)
151. [Pharvaris ACAAI 2020 press release (2020)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-presents-clinical-data-acaai-2020-demonstrating-safety)
152. [Pharvaris CIIC Spring 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/evidence-supporting-combined-use-deucrictibant-ir-deucrictibant)
153. [Pharvaris clinical hold press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022029851/phvs-ex991_6.htm)
154. [Pharvaris corporate presentation, January 2024 (2024)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024002680/phvs-ex99_2.htm)
155. [Pharvaris EAACI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/data-supporting-differentiated-profile-deucrictibant-hae)
156. [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)
157. [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm)
158. [Pharvaris Form 6-K, first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526219372/phvs-ex99_1.htm)
159. [Pharvaris Form 6-K, fourth quarter and full year 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000012/phvs-ex99_1.htm)
160. [Pharvaris Form 6-K, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm)
161. [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)
162. [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)
163. [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)
164. [Pharvaris Form F-1/A registration statement (2021)](https://www.sec.gov/Archives/edgar/data/1830487/000119312521023578/d50231df1a.htm)
165. [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)
166. [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)
167. [Pharvaris RAPIDe-3 Lancet publication press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/phase-3-study-results-highlighting-deucrictibants-rapid-and)
168. [Pharvaris RAPIDe-3 topline data presentation (2025)](https://ir.pharvaris.com/static-files/30661839-e400-44eb-a1e9-9ad88f75d404)
169. [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)
170. [Pharvaris RAPIDe-3 topline timing update press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525157363/d17337dex991.htm)
171. [Princic et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11963383/)
172. [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf)
173. [Riedl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24468257/)
174. [Riedl et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6186115/)
175. [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)
176. [Riedl et al. (2023b)](https://ir.pharvaris.com/static-files/1d0c218c-12ee-4a4e-93bc-b9c939dac963)
177. [Riedl et al. (2023c)](https://ir.pharvaris.com/static-files/0bae214b-7ff8-49ec-8340-1bb60a5935b9)
178. [Riedl et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819658/)
179. [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)
180. [Riedl et al. (2026b)](https://ir.pharvaris.com/static-files/2e62f03b-fbb8-4376-9151-f74c41dd8c0f)
181. [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)
182. [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)
183. [Shah et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37395381/)
184. [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)
185. [Tachdjian et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993116/)
186. [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)
187. [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)
188. [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)
189. [Troelnikov et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11239692/)
190. [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf)
191. [US Hereditary Angioedema Association](https://www.haea.org/)
192. [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)
193. [Valerieva et al. (2023)](https://ir.pharvaris.com/static-files/6555035a-ed16-406c-a522-2eb966f73df4)
194. [Valerieva et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11431061/)
195. [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)
196. [Vernon et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19597964/)
197. [Watt et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12895942/)
198. [Watt et al. (2026b)](https://link.springer.com/article/10.1186/s13023-025-04134-z)
199. [Wilson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20408341/)
200. [Wong et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35964924/)
201. [World Health Organization (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl126.pdf)
202. [Yong et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37146882/)
203. [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)
204. [Zanichelli et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26304015/)
205. [Zhang et al. (2025)](https://ir.pharvaris.com/static-files/1680a98e-6898-4ee8-afb4-12d1ff5eb47a)
206. [Zilberberg et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20964950/)
207. [Zilberberg et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22195693/)
208. [Zuraw and Christiansen (2026)](https://pubmed.ncbi.nlm.nih.gov/42849490/)
209. [Zuraw et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20920772/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
